VALNEVA SE WKN: A0MVJZ ISIN: FR0004056851 Kürzel: VLA Forum: Aktien Thema: Hauptdiskussion

So ein Schwachsinn immer. Das Minus ist dem Management von Val geschuldet! Wo ist denn die Br Zulassung? Wo sind denn die Umsätze und die Länder die Interesse hatten? Die ganzen Investoren der ständigen Konferenzen?! 😂😂😂

Komm V12 machen….

Einzig und alleine auf KEs kann man sich hier verlassen. Die kommen immer pünktlich 😂

Mal sehen ob VAL es für nötig empfindet, sich heute über den wieder geplatzten Termin bezüglich Anvisa zu äußern - das sieht so langsam wie seitens BR politisch gewollt aus. Oder wie es mit dem ‚Technologie-Transfer‘ zum SII aussieht, da waren jetzt auch bald vier Monate Zeit seit dem 19.12.

https://www.deraktionaer.de/artikel/pharma-biotech/valneva-starkes-produkt-neuer-schwung-fuer-die-aktie-20377580.html

Ja, ich denke das heutige Minus ist dem schwachen Gesamtmarkt zu verschulden.

Was man Valneva mal zu Gute halten muss (kann gar nicht glauben das ich so etwas sage) - wir halten uns "relativ" OK betrachtet man mal den Gesamtmarkt die letzten Wochen.

wenn bis ende April keine Zulassung - sind wir bei 2.xx - sowas von sinnlos hier

ich versteh auch VAL nicht, warum sie immer wieder Zeiten der Zulassung nennen (.. im letzt.Quartal 2024 erwartet, im 1. Qu. 25 erwartet usw), am Besten gar nichts melden uns sich "überraschen" lassen

Ist ja eh immer so dass sie die Leute anzuckern wollen mit einer Einreichung um dann später was negatives zu melden

Vielleicht kommt später noch eine Meldung. Wegen der Zeitverschiebung....😴

6 Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion - Valneva (https://valneva.com/press- release/valneva-responds-to-french-governments-call-for-vaccine-supply-of- ixchiq-against-chikungunya-outbreak-in-la-reunion/) 7 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine - Valneva (https://valneva.com/press- release/valneva-reports-further-positive-pivotal-phase-3-data-in-adolescents- for-its-single-shot-chikungunya-vaccine/) 8 Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - Valneva (https://valneva.com/press-release/valneva-reports-high-sustained-immune- response-in-adolescents-one-year-after-single-vaccination-with-its-chikungunya- vaccine/) 9 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine - Valneva (https://valneva.com/press-release/cepi-expands-partnership-with-valneva-with-a- 41-3-million-grant-to-support-broader-access-to-the-worlds-first-chikungunya- vaccine/) 10 Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - Valneva (https://valneva.com/press-release/valneva- successfully-expands-access-to-asia-for-its-chikungunya-vaccine-with-serum- institute-of-india/) 11 https://jvi.asm.org/content/jvi/88/20/11644.full.pdf 12 https://cmr.asm.org/content/31/1/e00104-16 13 PAHO/WHO data: Number of reported cases of chikungunya fever in the Americas (Cumulative Cases 2018-2023 and Cases per year 2013-2017). https://www.paho.org/data/index.php/en/mnu-topics/chikv-en/550-chikv-weekly-

1 Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ® - Valneva (https://valneva.com/press- release/valneva-receives-marketing-authorization-in-the-uk-for-the-worlds-first- chikungunya-vaccine-ixchiq/) 2 Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ (https://valneva.com/press-release/valneva- receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for- chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press-release/valneva- receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for- chikungunya-vaccine-ixchiq/) - Valneva (https://valneva.com/press- release/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label- extension-for-chikungunya-vaccine-ixchiq/) 3 Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-announces-u-s-fda-approval-of- worlds-first-chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press- release/valneva-announces-u-s-fda-approval-of-worlds-first-chikungunya-vaccine- ixchiq/) - Valneva (https://valneva.com/press-release/valneva-announces-u-s-fda- approval-of-worlds-first-chikungunya-vaccine-ixchiq/) 4 Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-receives- marketing-authorization-in-europe-for-the-worlds-first-chikungunya-vaccine- ixchiq/)(®) (https://valneva.com/press-release/valneva-receives-marketing- authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/) - Valneva (https://valneva.com/press-release/valneva-receives-marketing- authorization-in-europe-for-the-worlds-first-chikungunya-vaccine-ixchiq/) 5 Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ (https://valneva.com/press-release/valneva-announces-health- canada-approval-of-the-worlds-first-chikungunya-vaccine-ixchiq/)(®) (https://valneva.com/press-release/valneva-announces-health-canada-approval-of- the-worlds-first-chikungunya-vaccine-ixchiq/) - Valneva

large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has now been identified in over 110 countries in Asia, Africa, Europe and the Americas(12). Between 2013 and 2023, more than 3.7 million cases were reported in the Americas(13) and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem.(14) About Valneva SE We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines, including the world's first chikungunya vaccine, as well as certain third-party vaccines. Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced tetravalent Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com (http://www.valneva.com).

Valneva is focused on expanding the vaccine's label and access. Label extension applications to adolescent were submitted in Europe, the United-States, Canada and the UK based on positive six-month adolescent Phase 3 data which showed that a single-dose vaccination with IXCHIQ(®) induces a high and sustained immune response in 99.1% of adolescents, and that the vaccine was generally well tolerated(7). Valneva reported further positive Phase 3 data in adolescents earlier this year, which showed a sustained 98.3% sero-response rate one-year after single vaccination with IXCHIQ(®)(8). The Lancet Infectious Diseases, a world leading infectious diseases journal, also published an article (https://www.thelancet.com/journals/laninf/article/PIIS1473- 3099(24)00458-4/abstract) showing that the vaccine was well tolerated in adolescents aged 12 to 17 years 28 days after a single injection, regardless of previous chikungunya virus (CHIKV) infection. Additionally, in the third quarter of 2024, the Company expanded its partnership with the Coalition for Epidemic Preparedness (CEPI)(9), with support from the EU Horizon Europe program, through a $41.3 million grant to advance broader access to the vaccine in Low- and Middle-Income Countries (LMICs), post-marketing studies and research to support potential label extensions in children, adolescents and pregnant women. Within the framework of this partnership, Valneva recently announced the signing of an exclusive license agreement with the Serum Institute of India (SII)(10), the world's largest manufacturer of vaccines by number of doses, enabling the supply of the vaccine in Asia, with a commitment to priority supply of the chikungunya vaccine at an affordable price to public health markets in LMICs. This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an affordable price for distribution in Latin American countries and selected LMICs affected by the disease. About Chikungunya Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years(11).